FDA Approves Novartis Drug for Rare Kidney Disease Treatment [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to reduce proteinuria. C3G is a progressive and ultra-rare kidney disease that is typically diagnosed in young adults and often progresses to kidney failure. Per NVS, this is the first and only treatment approved for this condition. Data from the phase III APPEAR-C3G study supported the label expansion of the drug for this C3G indication. Fabhalta is an oral, Factor B inhibitor of the alternative complement pathway. Patients have been relying on supportive care, broad immunosuppression and symptom management so far for C3G. Shares of Novartis have risen 20.3% in the past year against the large cap pharmaceutical industry's decline of 2%. Image Source: Zacks
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosisPR Newswire
- Novartis Reports Updated Positive Data From Phase III SMA Program [Yahoo! Finance]Yahoo! Finance
- Novartis builds case for new SMA gene therapy [Yahoo! Finance]Yahoo! Finance
- Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)PR Newswire
- Acute Respiratory Distress Syndrome Market Forecast Report and Company Analysis 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun,Teva [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 1/31/25 - Beat
NVS
Sec Filings
- 1/31/25 - Form 6-K
- 1/31/25 - Form 6-K
- 1/31/25 - Form IRANNOTICE
- NVS's page on the SEC website